TINAVI(SH:688277) Xin Lang Zheng Quan·2025-09-16 05:28Core Viewpoint - Tianzhihang Medical Technology Co., Ltd. has shown significant stock performance and financial growth, particularly in the orthopedic surgical navigation robot sector, despite facing challenges in net profit. Group 1: Stock Performance - On September 16, Tianzhihang's stock rose by 2.10%, reaching 18.00 CNY per share, with a trading volume of 77.72 million CNY and a turnover rate of 0.97%, resulting in a total market capitalization of 8.148 billion CNY [1] - Year-to-date, Tianzhihang's stock price has increased by 80.18%, with a 1.24% rise over the last five trading days, an 8.49% decline over the last 20 days, and a 29.03% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 17, where it recorded a net purchase of 26.27 million CNY [1] Group 2: Company Overview - Tianzhihang, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots [2] - The company's revenue composition includes 58.31% from orthopedic surgical navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [2] - As of June 30, the number of shareholders decreased by 7.14% to 15,400, with an average of 29,308 circulating shares per person, an increase of 8.48% [2] Group 3: Financial Performance - For the first half of 2025, Tianzhihang reported revenue of 125 million CNY, a year-on-year increase of 114.89%, while the net profit attributable to shareholders was -57.55 million CNY, a decrease of 23.80% year-on-year [2] - As of June 30, 2025, the top ten circulating shareholders included Huaxia CSI Robot ETF, which holds 7.10 million shares as a new shareholder [2]